Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2)

The ability of the anti-diabetic drug metformin to inhibit anabolic processes including gluconeogenesis and lipogenesis is partly attributable to activation of the AMP-activated protein kinase (AMPK) pathway. The p160 steroid receptor coactivator 2 (SRC-2) is a key regulator of cellular metabolism a...

Descripción completa

Detalles Bibliográficos
Autores principales: Madsen, Andre, Bozickovic, Olivera, Bjune, Jan-Inge, Mellgren, Gunnar, Sagen, Jørn V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637908/
https://www.ncbi.nlm.nih.gov/pubmed/26548416
http://dx.doi.org/10.1038/srep16430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637908/
https://www.ncbi.nlm.nih.gov/pubmed/26548416
http://dx.doi.org/10.1038/srep16430

Ejemplares similares